U.S. Patent Disclosures
Tuesday, February 22, 2011
Asuragen Inc., of Austin, Texas, has received notices of allowance for claims related to the use of mir-21 and mir-30a as diagnostics in lung cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.